Výsledky vyhledávání - "Katharina, Modelska"

Exploring Spatial-Temporal Changes in 18F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide

Autor: Robert Jeraj, Alison Roth, William T. Duggan, Scott B. Perlman, Anna Ferrari, Joshua M. Lang, Jamie M. Sperger, Glenn Liu, Timothy Perk, Katharina Modelska, Anthony R. Porcari, Christos Kyriakopoulos, Elisabeth I. Heath, Anupama Singh

Publikováno v: Journal of Clinical Oncology. 38:3662-3671

PURPOSE Intrapatient treatment response heterogeneity is under-recognized. Quantitative total bone imaging (QTBI) using 18F-NaF positron emission tomography/computed tomography (PET/CT) scans is a tool that allows characterization of interlesional tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c2a0a588e9d8d5045236e38de32fcedb
https://doi.org/10.1200/jco.20.00348

Zobrazit plný text záznamu

Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer

Autor: Cora N, Sternberg, Karim, Fizazi, Fred, Saad, Neal D, Shore, Ugo, De Giorgi, David F, Penson, Ubirajara, Ferreira, Eleni, Efstathiou, Katarzyna, Madziarska, Michael P, Kolinsky, Daniel I G, Cubero, Bettina, Noerby, Fabian, Zohren, Xun, Lin, Katharina, Modelska, Jennifer, Sugg, Joyce, Steinberg, Maha, Hussain, R, Waterhouse

Publikováno v: Sternberg, C N, Fizazi, K, Saad, F, Shore, N D, de Giorgi, U, Penson, D F, Ferreira, U, Efstathiou, E, Madziarska, K, Kolinsky, M P, Cubero, D I G, Noerby, B, Zohren, F, Lin, X, Modelska, K, Sugg, J, Steinberg, J, Hussain, M & The PROSPER Investigators 2020, ' Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer ', New England Journal of Medicine, vol. 382, no. 23, pp. 2197-2206 . https://doi.org/10.1056/NEJMoa2003892
New England Journal of Medicine, 382(23), 2197-2206. MASSACHUSETTS MEDICAL SOC

Preliminary trial results showed that enzalutamide significantly improved metastasis-free survival among men who had nonmetastatic, castration-resistant prostate cancer and rapidly increasing prostate-specific antigen (PSA) levels while taking androg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ada3068f332332d3148bedbc332995e5
https://research.rug.nl/en/publications/55cc0758-3a20-4830-a0d2-94595129fd5f

Zobrazit plný text záznamu

Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study

Autor: Gopal Saha, Robert Leong, Kin-Hung Peony Yu, David H. Henry, Charles Bradley, Moshe Mittelman, Hetty E. Carraway, John A. Glaspy, Amy Zhou, Katharina Modelska, Rosemary Harrup, Pamela Bartels

Publikováno v: American journal of hematologyREFERENCES. 97(2)

Anemia is the predominant cytopenia in myelodysplastic syndromes (MDS) and treatment options are limited. Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor approved for the treatment of anemia of chronic kidney disease in the UK,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89aae2a06185055db76ebbbd942da3e1
https://pubmed.ncbi.nlm.nih.gov/34724251

Zobrazit plný text záznamu

Open-label, phase 2 study of roxadustat for treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies

Autor: John A. Glaspy, Nashat Y Gabrail, Patricia A. Locantore-Ford, Gopal C Saha, Elise Hardy, Tyson Lee, Katharina Modelska, David H. Henry

Publikováno v: Journal of Clinical Oncology. 40:12085-12085

12085 Background: Anemia is prevalent in patients (pts) receiving myelosuppressive chemotherapy (> 60%) and exacerbated by repeated treatment cycles due to cytotoxic agent accumulation. Chemotherapy-induced anemia (CIA) management options are subopti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bfbe44274a12f4ab47c6f5575b566ac3
https://doi.org/10.1200/jco.2022.40.16_suppl.12085

Zobrazit plný text záznamu

Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring

Autor: Bettina Noerby, Neal D. Shore, Cora N. Sternberg, Xun Lin, Karim Fizazi, Fred Saad, Eleni Efstathiou, Maha Hussain, Joyce Steinberg, Jennifer Sugg, Katharina Modelska

Publikováno v: Saad, F, Sternberg, C N, Efstathiou, E, Fizazi, K, Modelska, K, Lin, X, Sugg, J, Steinberg, J, Noerby, B, Shore, N D & Hussain, M 2020, ' Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer : Any Rise in Prostate-specific Antigen May Require Closer Monitoring ', European Urology, vol. 78, no. 6, pp. 847-853 . https://doi.org/10.1016/j.eururo.2020.08.025

Background: There is no universally accepted definition for prostate-specific antigen (PSA) progression. However, changes in PSA in patients with castration-resistant prostate cancer (CRPC) are used to inform treatment decisions. Objective: To determ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::820a0ca988c5ed4d1e0d672cfeefb250
https://pubmed.ncbi.nlm.nih.gov/32958300

Zobrazit plný text záznamu

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

Autor: Maha Hussain, Karim Fizazi, Neal D. Shore, Andrew Krivoshik, Per Rathenborg, Katharina Modelska, De Phung, Ubirajara Ferreira, Fred Saad, Petro Ivashchenko, Eren Demirhan, Cora N. Sternberg

Publikováno v: N Engl J Med

BACKGROUND: Men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising prostate-specific antigen (PSA) level are at high risk for metastasis. We hypothesized that enzalutamide, which prolongs overall survival among patients wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::216a8fc4d2ea605bd9960f06b162561d
https://doi.org/10.1056/nejmoa1800536

Zobrazit plný text záznamu

PD15-07 IMPACT OF BONE-TARGETED THERAPIES IN PATIENTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER ON ENZALUTAMIDE: A POST HOC ANALYSIS OF PREVAIL

Autor: Janet Kim, Joyce Steinberg, Neal D. Shore, Karim Fizazi, Ping Lin, Fred Saad, Tomasz M. Beer, Katharina Modelska

Publikováno v: Journal of Urology. 201

INTRODUCTION AND OBJECTIVES:Enzalutamide (ENZA) prolongs radiographic progression-free survival (rPFS) and overall survival (OS) in men with chemotherapy-naive metastatic castration-resistant prost...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5604b5fa1761a59b7fc41088565f7647
https://doi.org/10.1097/01.ju.0000555460.30099.9f

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání